Omnicell/$OMCL
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Omnicell
Omnicell Inc provides automation and business analytics software for healthcare providers. The company is engaged in transforming the pharmacy and nursing care delivery model. The company helps its customers define and deliver cost-effective medication management designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks and drive improved clinical, operational, and financial outcomes across all care settings. The company derives the majority of its revenue from the United States.
- Ticker
- $OMCL
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 3,485
- Headquarters
- Fort Worth, United States
- Website
- www.omnicell.com
Omnicell Metrics
BasicAdvanced
$1.5B
39.93
$0.84
0.97
-
Price and volume
Market cap
$1.5B
Beta
0.97
52-week high
$55.00
52-week low
$29.06
Average daily volume
580K
Financial strength
Current ratio
1.644
Quick ratio
1.16
Long term debt to equity
0.146
Total debt to equity
0.146
Interest coverage (TTM)
12.62%
Profitability
EBITDA (TTM)
97.814
Gross margin (TTM)
45.27%
Net profit margin (TTM)
3.13%
Operating margin (TTM)
4.05%
Effective tax rate (TTM)
36.08%
Revenue per employee (TTM)
$360,000
Management effectiveness
Return on assets (TTM)
1.52%
Return on equity (TTM)
3.06%
Valuation
Price to earnings (TTM)
39.931
Price to revenue (TTM)
1.222
Price to book
1.19
Price to tangible book (TTM)
3.89
Price to free cash flow (TTM)
12.256
Free cash flow yield (TTM)
8.16%
Free cash flow per share (TTM)
2.742
Growth
Revenue change (TTM)
8.45%
Earnings per share change (TTM)
70.73%
3-year revenue growth (CAGR)
0.31%
10-year revenue growth (CAGR)
7.60%
3-year earnings per share growth (CAGR)
16.83%
10-year earnings per share growth (CAGR)
7.88%
What the Analysts think about Omnicell
Analyst ratings (Buy, Hold, Sell) for Omnicell stock.
Analyst projections of the future price of Omnicell stock.
Bulls say / Bears say
Omnicell’s second-quarter revenue rose 7% year on year to $312 million, while first-half operating cash flow reached $123 million. It raised 2026 adjusted EBITDA guidance to $175 million-$185 million and adjusted EPS guidance to $2.15-$2.30, with $292 million of cash and no revolver borrowings at the quarter end. (Omnicell, SEC filing)
Omnicell is expanding beyond hardware into more embedded software and compliance workflows. SaaS, Expert Services and technical services grew in the second quarter, while a new TraceLink integration puts drug-traceability functions inside Omnicell’s central pharmacy workflow. (Omnicell, OTC Markets)
Some of the second-quarter profit lift was temporary: a $15 million tariff refund reduced product costs and will not recur. Omnicell also expects memory-chip costs to add about $6 million in the second half of 2026, putting pressure on margins. (SEC filing, Sharewise)
Valuation leaves less room for execution disappointments. A September review put Omnicell at about 38.3 times earnings, above the medical-equipment industry average of 24.5 times and the peer average of 28.5 times. (Simply Wall St)
Data summarised monthly by Lightyear AI. Last updated on 23 Sept 2026.
Omnicell Financial Performance
Revenues and expenses
Omnicell Earnings Performance
Company profitability
Upcoming events
No upcoming events
Omnicell News
AllArticlesVideos
Funds containing Omnicell
AllUSDGBPEUR
Fund name | Fund size | $OMCL weighting |
|---|---|---|
iShares S&P SmallCap 600$IDP6 | $3.2B | 0.09% |
iShares S&P Small Cap 600£ISP6 | £2.4B | 0.09% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.05% |
SPDR Russell 2000 US Small Cap£R2SC | £4.1B | 0.05% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | €2.8B | 0.05% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.